1 / 16

Accelerating Oncology Clinical Development in Asia

Accelerating Oncology Clinical Development in Asia. Pharma Trials Asia 2010, Singapore 18th March. Dr. Ross Horsburgh, VP Asia/Pacific, Kendle International. What’s happened so far. Prehistory. Asia Different. Asia Big. Asia Global. Pre 1990 Ad-hoc Investigator-interest trials.

RoyLauris
Download Presentation

Accelerating Oncology Clinical Development in Asia

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Accelerating Oncology Clinical Development in Asia Pharma Trials Asia 2010, Singapore 18th March Dr. Ross Horsburgh, VP Asia/Pacific, Kendle International

  2. What’s happened so far Prehistory AsiaDifferent AsiaBig AsiaGlobal Pre 1990 Ad-hoc Investigator-interest trials Early 90’s Asia specific diseases or questions Late 90’s Large scale trials Rescue studies NOW Inclusion in global development

  3. Oncology already a key area for Asia

  4. IRESSA still a great case study for Asia ISEL trial: -5 Asian markets (Taiwan, Thailand, Singapore, Malaysia, Philippines) - 342 Asian patients of total 1692 globally Overall no difference in survival Iressa vs. placebo However pre-planned sub-group analysis of Asian patient cohort showed significant benefit

  5. Oncology DD in Asia was metrics-driven

  6. Oncology now full spectrum in Asia

  7. The questions have evolved Prehistory AsiaDifferent AsiaBig AsiaGlobal Should we? Do what? How toBuild? How tooptimise? 7

  8. Asia’s important differences Large population Lower costs (espec. Procedures) Fast execution Focus on science & education Lack of legacy systems / mindset Rapid growth High rate of change(sites / personnel / CRO’s / newco’s / regulations)

  9. Ensure you think “strategic opportunities” not “operational issues” No unique operational challenges Asia wont follow EU / USA “if it looks like they did is it the best approach?” Winners will best exploit the differences Asia’s greatest contribution will be innovation - process - science / products

  10. (1) Drive Efficiencies Large population Lower costs (espec. Procedures) Fast execution Focus on science & education Lack of legacy systems / mindset Rapid growth High rate of change(sites / personnel / CRO’s / newco’s / regulations) 10

  11. (2) Leverage the science & innovation Large population Lower costs (espec. Procedures) Fast execution Focus on science & education Lack of legacy systems / mindset Rapid growth High rate of change(sites / personnel / CRO’s / newco’s / regulations) 11

  12. (3) Maximise Market Access returns Large population Lower costs (espec. Procedures) Fast execution Focus on science & education Lack of legacy systems / mindset Rapid growth High rate of change(sites / personnel / CRO’s / newco’s / regulations) 12

  13. Where are the best centres for oncology? KOREA‘R’ as well as ‘D’ CHINAToughest, but biggest market access upside TAIWAN-long pedigree in Oncology INDIA Great metricsGreat innovation PHILIPPINES- consistent performer SINGAPORE - fast to start, predictable regulatory, Ph1 & Translational

  14. What is the role of outsourcing? Tactical Local CRO Do it yourself CRO do it all Global CRO Strategic 14

  15. Summary Asia is already a key region for Oncology DD Asia is different- Think strategic +ve not operational –ve Open mind on what / how / how much / where to outsource and maximise the CRO’s added value

More Related